Circulating Beta3-Adrenoreceptor as Novel Independent Biomarker for Risk Assessment in Neuroblastoma Patients.
A circulating immune receptor may improve neuroblastoma risk assessment when combined with existing staging tools.
Circulating beta3-adrenoreceptor is identified as a novel independent biomarker for neuroblastoma risk assessment that may complement existing staging markers. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- retrospective biomarker study
- Category
- early_cancer_detection
- Maturity
- Validated
- Journal
- FASEB J
Why it surfaced
Novel liquid biomarker for neuroblastoma, a rare pediatric cancer with significant unmet need for non-invasive monitoring and risk stratification.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.